Tobias Zimmermann

Consultant / Senior Researcher

University Hospital Basel
Country flagSwitzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (18)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Aims We aimed to test the hypothesis if combining coronary artery calcium score (Ca-score) as a quantitative anatomical marker of coronary atherosclerosis with high-sensitivity cardiac troponin as a quantitative biochemical marker of myocardial injury provided incremental value in the detection of functionally relevant coronary artery disease (fCAD) and risk stratification. Methods and results Consecutive patients undergoing myocardial perfusion single-photon emission computed tomography (MPS) without prior CAD were enrolled. The diagnosis of fCAD was based on the presence of ischaemia on MPS and coronary angiography; fCAD was centrally adjudicated in the diagnostic and prognostic domain. Diagnostic accuracy was evaluated using the area under the receiver-operating characteristic curve (AUC). The composite of cardiovascular death and non-fatal acute myocardial infarction (AMI) within 730 days was the primary prognostic endpoint. Among 1715 patients eligible for the diagnostic analysis, 399 patients had fCAD. The combination of Ca-score and high-sensitivity cardiac troponin T (hs-cTnT) had good diagnostic accuracy for the diagnosis of fCAD (AUC 0.79, 95% confidence interval (CI) 0.77–0.81), but no incremental value compared with the Ca-score alone (AUC 0.79, 95% CI 0.77–0.81, P = 0.965). Similar results were observed using high-sensitivity cardiac troponin I (AUC 0.80, 95% CI 0.77–0.82) instead of hs-cTnT. Among 1709 patients (99.7%) with available follow-up, 59 patients (3.5%) suffered the composite primary prognostic endpoint (non-fatal AMI, n = 34; CV death, n = 28). Both Ca-score and hs-cTnT had independent prognostic value. Increased risk was restricted to patients with elevation in both markers. Conclusion The combination of the Ca-score with hs-cTnT increases the prognostic accuracy for future events but does not provide incremental value vs. the Ca-score alone for the diagnosis of fCAD. Study registration Clinical trial registration: NCT00470587.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (16)

Mervyn Singer

University College London

UNITED KINGDOM
View details

Michael J Zellweger

MD/ Professor of Cardiology

University Hospital Basel

SWITZERLAND
View details

Johannes Tobias Neumann

University Heart and Vascular Center Hamburg

GERMANY
View details

Sven Knecht

Technical Leader Electrophysiology

University Hospital Basel

SWITZERLAND
View details

Hamid MERDJI

Associate Professor of Intensive Care Medicine

University of Strasbourg

FRANCE
View details

Simon Adrian Amacher

University Hospital Basel

SWITZERLAND
View details

Dimitrios Doudesis

BHF Principal Investigator | Senior Data Scientist

University of Edinburgh

UNITED KINGDOM
View details

Michael Christ

Head

Luzerner Kantonsspital

SWITZERLAND
View details

Caroline E. Gebhard

University Hospital Basel

SWITZERLAND
View details

Vera Regitz-Zagrosek

Director, Prof. dr. Dr

Charité - Universitätsmedizin Berlin

GERMANY
View details

Michael Kunz

University Hospital Basel

SWITZERLAND
View details

Thomas Nestelberger

University Hospital Basel

SWITZERLAND
View details

Andreas Buser

Prof. Dr. med. , Head Transfusion Medicine

University Hospital Basel

SWITZERLAND
View details

Matthias Diebold

University Hospital Basel

SWITZERLAND
View details

Pedro Lopez Ayala

University Hospital Basel

SWITZERLAND
View details

Cass Li

University of Edinburgh

UNITED KINGDOM
View details